Effectiveness of sitafloxacin monotherapy for quinolone-resistant rectal and urogenital Mycoplasma genitalium infections: a prospective cohort study
Open Access
- 28 June 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 78 (8) , 2070-2079
Abstract
Mycoplasma genitalium has a tendency to develop macrolide and quinolone resistance. We investigated the microbiological cure rate of a 7 day course of sitafloxacin for the treatment of rectal and urogenital infections in MSM. This open-label, prospective cohort study was conducted at the National Center for Global Health and Medicine, Tokyo, Japan from January 2019 to August 2022. Patients with M. genitalium urogenital or rectal infections were included. The patients were treated with sitafloxacin 200 mg daily for 7 days. M. genitalium isolates were tested for parC, gyrA and 23S rRNA resistance-associated mutations. In total, 180 patients (median age, 35 years) were included in this study, of whom 77.0% (97/126) harboured parC mutations, including 71.4% (90/126) with G248T(S83I) in parC, and 22.5% (27/120) harboured gyrA mutations. The median time to test of cure was 21 days. The overall microbiological cure rate was 87.8%. The cure rate was 100% for microbes harbouring parC and gyrA WTs, 92.9% for microbes harbouring parC G248T(S83I) and gyrA WT, and 41.7% for microbes harbouring parC G248T(S83I) and gyrA with mutations. The cure rate did not differ significantly between urogenital and rectal infection (P = 0.359). Sitafloxacin monotherapy was highly effective against infection caused by M. genitalium, except strains with combined parC and gyrA mutations. Sitafloxacin monotherapy can be used as a first-line treatment for M. genitalium infections in settings with a high prevalence of parC mutations and a low prevalence of gyrA mutations.Keywords
Funding Information
- National Center for Global Health and Medicine (19A1002, 20A1020)
This publication has 51 references indexed in Scilit:
- Treatment of rectal chlamydia infection may be more complicated than we originally thoughtJournal of Antimicrobial Chemotherapy, 2014
- Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistanceInternational Journal of STD & AIDS, 2013
- Effect of HIV and Chlamydia Infection on Rectal Inflammation and Cytokine Concentrations in Men Who Have Sex with MenClinical and Vaccine Immunology, 2013
- Fluoroquinolone and Macrolide Resistance-Associated Mutations in Mycoplasma genitaliumJournal of Clinical Microbiology, 2013
- Differing Neisseria gonorrhoeae Bacterial Loads in the Pharynx and Rectum in Men Who Have Sex with Men: Implications for Gonococcal Detection, Transmission, and ControlJournal of Clinical Microbiology, 2011
- Mycoplasma genitalium: from Chrysalis to Multicolored ButterflyClinical Microbiology Reviews, 2011
- Azithromycin Treatment Failure inMycoplasma genitalium–Positive Patients with Nongonococcal Urethritis Is Associated with Induced Macrolide ResistanceClinical Infectious Diseases, 2008
- Short tandem repeat sequences in the Mycoplasma genitalium genome and their use in a multilocus genotyping systemBMC Microbiology, 2008
- Single-Nucleotide Polymorphisms in the rRNA Operon and Variable Numbers of Tandem Repeats in the Lipoprotein Gene among Mycoplasma genitalium Strains from Clinical SpecimensJournal of Clinical Microbiology, 2004
- Use of TaqMan 5′ Nuclease Real-Time PCR for Quantitative Detection of Mycoplasma genitalium DNA in Males with and without Urethritis Who Were Attendees at a Sexually Transmitted Disease ClinicJournal of Clinical Microbiology, 2004